subscribeSubscribe
Roche writes off $3B on lower sales forecasts for gene therapies, cancer drugs

Roche writes off $3B on lower sales forecasts for gene therapies, cancer drugs
BIOPHARMADIVE
03 Feb 2023
Share Share
Novartis and the (pCPA) conclude negotiations for Luxturna

Novartis and the (pCPA) conclude negotiations for Luxturna
NEWSWIRE
20 Sep 2022
Share Share
In vivo gene editing grabs the spotlight after Intellia triumph

In vivo gene editing grabs the spotlight after Intellia triumph
Arlene Weintraub FIERCEBIOTECH
29 Sep 2021
Share Share
Luxturna inventor launches new gene therapy biotech with $19M

Luxturna inventor launches new gene therapy biotech with $19M
Kyle LaHucik FIERCEBIOTECH
23 Sep 2021
Share Share
Horama refuels with a Series B expansion and a new name

Horama refuels with a Series B expansion and a new name
Nicole DeFeudis ENDPTS
20 Jul 2021
Share Share
First patient undergoes Luxturna gene therapy on NHS

First patient undergoes Luxturna gene therapy on NHS
Anna Smith PHARMATIMES
18 Feb 2020
Share Share
Manufacturing: the next breakthrough in gene therapy

Manufacturing: the next breakthrough in gene therapy
DIANE BLUMENTHAL STATNEWS
19 Dec 2019
Share Share
Aldevron, NTC Team Up for Gene Therapy Manufacturing

Aldevron, NTC Team Up for Gene Therapy Manufacturing
CONTRACT PHARMA
24 Oct 2019
Share Share
ProQR eye-disease data lend confidence that pivotal trial will succeed

ProQR eye-disease data lend confidence that pivotal trial will succeed
BIOPHARMADIVE
11 Oct 2019
Share Share
Roche and Spark Continue to See Delays for Pending Deal

Roche and Spark Continue to See Delays for Pending Deal
Alex Keown BIOSPACE
07 Sep 2019
Share Share